Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF-collagen interaction

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 10, 2009, Pages 1680-1687

  Szanto, T ^a,b   Vanhoorelbeke, K ^b   Toth, G ^c   Vandenbulcke, A ^b   Toth, J ^a   Noppe, W ^b   Deckmyn, H ^b   Harsfalvi, J ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Antithrombotic therapy; Collagen; Peptide inhibitor; Phage display; Platelet adhesion; Von Willebrand factor

Indexed keywords

ANTITHROMBOCYTIC AGENT; COLLAGEN; EPITOPE; TYROSYLASPARTYLPROLYLTRYPTOPHYLTHREONYLPROLYLSERINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AMINO ACID SEQUENCE; ARTICLE; BIOPANNING; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELETION MUTANT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; HUMAN; NORMAL HUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SHEAR STRESS; STEREOSPECIFICITY; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION;

COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EPITOPE MAPPING; FIBRINOLYTIC AGENTS; HEMORHEOLOGY; HUMANS; OLIGOPEPTIDES; PEPTIDE LIBRARY; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; STRESS, MECHANICAL; VON WILLEBRAND FACTOR;

EID: 70350020437     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03552.x     Document Type: Article

References (48)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002, 8:1227-34.
2. Sixma JJ, van Zanten GH, Huizinga EG, van der Plas RM, Verkley M, Wu YP, Gros P, de Groot PG. Platelet adhesion to collagen: an update. Thromb Haemost 1997, 78:434-8.
3. Moroi M, Jung SM, Nomura S, Sekiguchi S, Ordinas A, Diaz-Ricart M. Analysis of the involvement of the von Willebrand factor-glycoprotein Ib interaction in platelet adhesion to a collagen-coated surface under flow conditions. Blood 1997, 90:4413-24.
4. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998, 94:657-66.
5. Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 2000, 275:7539-46.
6. Doggett TA, Girdhar G, Lawshe A, Schmidtke DW, Laurenzi IJ, Diamond SL, Diacovo TG. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-VWF tether bond. Biophys J 2002, 83:194-205.
7. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985, 318:470-2.
8. Santoro SA. Identification of a 160,000 dalton platelet membrane protein that mediates the initial divalent cation-dependent adhesion of platelets to collagen. Cell 1986, 46:913-20.
9. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin alpha2beta1. Cell 2000, 101:47-56.
10. Siljander PR, Munnix IC, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, Farndale RW, Heemskerk JW. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004, 103:1333-41.
11. Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight CG, Farndale RW, Okuma M, Barnes MJ. Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 1998, 91:491-9.
12. Schoolmeester A, Vanhoorelbeke K, Katsutani S, Depraetere H, Feys HB, Heemskerk JM, Hoylaerts MF, Deckmyn H. Monoclonal antibody IAC-1 is specific for activated {alpha}2{beta}1 and binds to amino acids 199 to 201 of the integrin {alpha}2 I-domain. Blood 2004, 104:390-6.
13. van de Walle GR, Schoolmeester A, Iserbyt BF, Cosemans JM, Heemskerk JW, Hoylaerts MF, Nurden A, Vanhoorelbeke K, Deckmyn H. Activation of {alpha}IIb{beta}3 is a sufficient but also an imperative prerequisite to activate {alpha}2{beta}1 on platelets. Blood 2006, 109:595-602.
14. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the responsive integrin. Cell 1991, 65:359-62.
15. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest 2000, 105:783-91.
16. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem 1991, 196:369-75.
17. Nakayama T, Matsushita T, Dong Z, Sadler JE, Jorieux S, Mazurier C, Meyer D, Kojima T, Saito H. Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by the CYS1272-CYS1458 disulfide bond. J Biol Chem 2002, 277:22063-72.
18. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, Gros P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002, 297:1176-9.
19. Schneider SW, Nuschele S, Wixforth A, Gorzelanny C, Alexander-Katz A, Netz RR, Schneider MF. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA 2007, 104:7899-903.
20. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost 2007, 5:1363-70.
21. Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, Vanhoorelbeke K, Deckmyn H. Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem 2006, 281:4699-707.
22. Lankhof H, van Hoeij M, Schiphorst ME, Bracke M, Wu YP, Ijsseldijk MJ, Vink T, de Groot PG, Sixma JJ. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost 1996, 75:950-8.
23. Huizinga EG, Martijn van der Plas R, Kroon J, Sixma JJ, Gros P. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding. Structure 1997, 5:1147-56.
24. Romijn RA, Westein E, Bouma B, Schiphorst ME, Sixma JJ, Lenting PJ, Huizinga EG. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem 2003, 278:15035-9.
25. Vanhoorelbeke K, Ulrichts H, van de Walle G, Fontayne A, Deckmyn H. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des 2007, 13:2684-97.
26. De Meyer SF, Vanhoorelbeke K, Broos K, Salles II, Deckmyn H. Antiplatelet drugs. Br J Haematol 2008, 142:515-28.
27. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002, 22:323-8.
28. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol 1997, 122:165-71.
29. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, Roodt JP, Novak L, Harsfalvi J, Deckmyn H, Kotzé HF. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000, 20:1347-53.
30. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H, Kotze HF, Deckmyn H. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 2002, 99:3623-8.
31. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007, 115:2323-30.
32. Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJ, Bracke M, Furlan M, Tsai HM, de Groot PG, Sixma JJ, Vink T. Von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost 1997, 77:1008-13.
33. Lankhof H, Wu YP, Vink T, Schiphorst ME, Zerwes HG, de Groot PG, Sixma JJ. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor. Blood 1995, 86:1035-42.
34. Ulrichts H, Depraetere H, Harsfalvi J, Deckmyn H. Selection of phages that inhibit VWF interaction with collagen under both static and flow conditions. Thromb Haemost 2001, 86:630-5.
35. Noppe W, Vanhoorelbeke K, Galaev IY, Mattiasson B, Deckmyn H. A probe for capture and Fe3+induced conformational change of lactoferrin selected from phage displayed peptide libraries. J Dairy Sci 2004, 87:3247-55.
36. Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Westra DF, Romo G, Huizinga EG, Lopez JA, Berndt MC, Harsfalvi J, Deckmyn H. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001, 98:652-60.
37. Vanhoorelbeke K, Depraetere H, Romijn RA, Huizinga EG, De Maeyer M, Deckmyn H. A consensus tetra-peptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the VWF-collagen interaction. J Biol Chem 2003, 278:37815-21.
38. Szarvas M, Oparaugo P, Udvardy ML, Tóth J, Szántó T, Daróczi L, Vereb G, Hársfalvi J. Differential platelet deposition onto collagen in cone-and-plate and parallel plate flow chambers. Platelets 2006, 17:185-90.
39. Vanhoorelbeke K, Pareyn I, Schlammadinger A, Vauterin S, Hoylaerts MF, Arnout J, Deckmyn H. Plasma glycocalicin as a source of GPlb alpha in the von Willebrand factor ristocetin cofactor ELISA. Thromb Haemost 2005, 93:165-71.
40. Hoylaerts MF, Yamamoto H, Nuyts K, Vreys I, Deckmyn H, Vermylen J. Von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochem J 1997, 324:185-91.
41. Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, Deckmyn H. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008, 100:670-7.
42. Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost 2006, 95:469-75.
43. Zahger D, Fishbein MC, Garfinkel LI, Shah PK, Forrester JS, Regnstrom J, Yano J, Cercek B. VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. Circulation 1995, 92:1269-73.
44. Gurevitz O, Goldfarb A, Hod H, Feldman M, Shenkman B, Varon D, Eldar M, Inbal A. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arterioscler Thromb Vasc Biol 1998, 18:200-7.
45. Smith GP, Petrenko VA. Phage Display. Chem Rev 1997, 97:391-410.
46. Munoz Cdel C, Campbell W, Constantinescu I, Gyongyossy-Issa MI. Rational design of antithrombotic peptides to target the von Willebrand factor (vWf)-GPIb integrin interaction. J Mol Model 2008, 14:1191-202.
47. Benard SA, Smith TM, Cunningham K, Jacob J, DeSilva T, Lin L, Shaw GD, Kriz R, Kelleher KS. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation. Biochemistry 2008, 47:4674-82.
48. Bonnefoy A, Romijn RA, Vandervoort PA, Van Rompaey I, Vermylen J, Hoylaerts MF. Von Willebrand factor A1 domain can adequately substitute for A3 domain in recruitment of flowing platelets to collagen. J Thromb Haemost 2006, 4:2151-61.